Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A | P28223 | 3/20 | 0.39 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.38 |
| ▸ | PARP1 | P09874 | 1/20 | 0.34 |
| ▸ | CA1 | P00915 | 1/20 | 0.34 |
| ▸ | CA2 | P00918 | 1/20 | 0.34 |
| ▸ | GRIN2D | O15399 | 1/20 | 0.33 |
| ▸ | GRIN3B | O60391 | 1/20 | 0.33 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.33 |
| ▸ | GRIN2A | Q12879 | 1/20 | 0.33 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.33 |
| ▸ | GRIN2C | Q14957 | 1/20 | 0.33 |
| ▸ | GRIN3A | Q8TCU5 | 1/20 | 0.33 |
| ▸ | IDO1 | P14902 | 1/20 | 0.33 |
| ▸ | MAOA | P21397 | 1/20 | 0.33 |
| ▸ | MAOB | P27338 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | TP53 | P04637 | 1/20 | 0.33 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL269189 | 1.00 | HTR2A (0.39) | HTR2ACYP2D6PARP1CA1CA2 | |
| SCHEMBL12228571 | 0.78 | — | — | |
| SCHEMBL16870529 | 0.78 | GRIN2D (0.45) | HTR2AGRIN2DGRIN3BGRIN1GRIN2A | |
| SCHEMBL30968744 | 0.78 | — | — | |
| SCHEMBL22295673 | 0.76 | HTR2A (0.39) | HTR2ACYP2D6PARP1CA1CA2 | |
| SCHEMBL20146261 | 0.76 | HTR2A (0.47) | HTR2AIDO1HTR2CHRH1 | |
| SCHEMBL1276091 | 0.75 | HTR2A (0.50) | HTR2ACYP2D6MAOAMAOBKDM4E | |
| SCHEMBL31099344 | 0.75 | HTR2A (0.50) | HTR2ACYP2D6MAOAMAOBKDM4E | |
| SCHEMBL15233622 | 0.75 | PARP1 (0.36) | HTR2ACYP2D6PARP1CA1CA2 | |
| SCHEMBL1143179 | 0.75 | PARP1 (0.36) | HTR2ACYP2D6PARP1CA1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 59 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4389152-A1 | CONJUGATES OF PBD PRODRUGS | Synaffix B.V. (NL) | 2024-06-26 | — | — | EP | disclosed |
| US-20230302038-A1 | RNAS FOR COMPLEMENT INHIBITION | SIXTH STREET LENDING PARTNERS | 2023-09-28 | — | — | US | disclosed |
| WO-2023060858-A1 | MONOCHROMATIC FLUORESCENCE MRT GENE SEQUENCING REAGENT AND METHOD BASED ON ENVIRONMENT-SENSITIVE DYE | 深圳铭毅智造科技有限公司 | 2023-04-20 | — | — | WO | disclosed |
| US-20230114866-A1 | VIA CYCLOADDITION BILATERALLY FUNCTIONALIZED ANTIBODIES | SYNAFFIX B.V. (NL) | 2023-04-13 | — | — | US | disclosed |
| US-20230009757-A1 | COMBINATION THERAPY FOR C3 INHIBITION | APELLIS PHARMACEUTICALS, INC. (US) | 2023-01-12 | — | — | US | disclosed |
| US-20220409773-A1 | TRANSPLANTATION DEVICE USING CHEMICALLY CROSSLINKED ALGINIC ACID | MOCHIDA PHARMACEUTICAL CO., LTD. (JP) | 2022-12-29 | — | — | US | disclosed |
| US-11254720-B2 | Methods and systems for designing and/or characterizing soluble lipidated ligand agents | ON TARGET THERAPEUTICS LLC (US) | 2022-02-22 | — | — | US | disclosed |
| US-20210401997-A1 | DOSING REGIMENS AND RELATED COMPOSITIONS AND METHODS | SIXTH STREET LENDING PARTNERS | 2021-12-30 | — | — | US | disclosed |
| WO-2021125279-A1 | CHEMICALLY CROSSLINKED ALGINATE GEL FIBER | 持田製薬株式会社 | 2021-06-24 | — | — | WO | disclosed |
| EP-3808783-A1 | NOVEL CROSSLINKED ALGINIC ACID | Mochida Pharmaceutical Co., Ltd. (JP) | 2021-04-21 | — | — | EP | disclosed |
| US-20120172575-A1 | ALKYNES AND METHODS OF REACTING ALKYNES WITH 1,3-DIPOLE-FUNCTIONAL COMPOUNDS | UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC. (US) | 2012-07-05 | — | — | US | disclosed |
| US-20120172575-A1 | ALKYNES AND METHODS OF REACTING ALKYNES WITH 1,3-DIPOLE-FUNCTIONAL COMPOUNDS | UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC. (US) | 2012-07-05 | — | — | US | disclosed |
| US-8133515-B2 | Alkynes and methods of reacting alkynes with 1,3-dipole-functional compounds | UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC. (US) | 2012-03-13 | — | — | US | disclosed |
| US-8133515-B2 | Alkynes and methods of reacting alkynes with 1,3-dipole-functional compounds | UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC. (US) | 2012-03-13 | — | — | US | disclosed |
| US-20120040011-A9 | ALKYNES AND METHODS OF REACTING ALKYNES WITH 1,3-DIPOLE-FUNCTIONAL COMPOUNDS | UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC. (US) | 2012-02-16 | — | — | US | disclosed |
| US-20120040011-A9 | ALKYNES AND METHODS OF REACTING ALKYNES WITH 1,3-DIPOLE-FUNCTIONAL COMPOUNDS | UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC. (US) | 2012-02-16 | — | — | US | disclosed |
| WO-2011100131-A9 | MONOMERS AND OLIGONUCLEOTIDES COMPRISING CYCLOADDITION ADDUCT(S) | ALNYLAM PHARMACUTICALS, INC. (US) | 2011-10-20 | — | — | WO | disclosed |
| WO-2011100131-A2 | MONOMERS AND OLIGONUCLEOTIDES COMPRISING CYCLOADDITION ADDUCT(S) | ALNYLAM PHARMACUTICALS, INC. (US) | 2011-08-18 | — | — | WO | disclosed |
| US-20100297250-A1 | ALKYNES AND METHODS OF REACTING ALKYNES WITH 1,3-DIPOLE-FUNCTIONAL COMPOUNDS | UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC. (US) | 2010-11-25 | — | — | US | disclosed |
| US-20100297250-A1 | ALKYNES AND METHODS OF REACTING ALKYNES WITH 1,3-DIPOLE-FUNCTIONAL COMPOUNDS | UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC. (US) | 2010-11-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11254720-B2 | Methods and systems for designing and/or characterizing soluble lipidated ligand agents | LDLR, HDLBP, LIPG | HTR2A 3482/4885CYP2D6 3622/4885PARP1 4837/4885 |
| US-20230114866-A1 | VIA CYCLOADDITION BILATERALLY FUNCTIONALIZED ANTIBODIES | FUT5, FUCA1, FUT6 | HTR2A 3561/4885CYP2D6 2066/4885PARP1 232/4885 |
| US-20230009757-A1 | COMBINATION THERAPY FOR C3 INHIBITION | C3AR1, C5, CFH | HTR2A 2549/4885CYP2D6 4575/4885PARP1 109/4885 |
| US-20100297250-A1 | ALKYNES AND METHODS OF REACTING ALKYNES WITH 1,3-DIPOLE-FUNCTIONAL COMPOUNDS | ALG1, ST3GAL3, B3GNT2 | HTR2A 2987/4885CYP2D6 1242/4885PARP1 373/4885 |
| US-20120040011-A9 | ALKYNES AND METHODS OF REACTING ALKYNES WITH 1,3-DIPOLE-FUNCTIONAL COMPOUNDS | ALG1, ST3GAL3, B3GNT2 | HTR2A 2987/4885CYP2D6 1242/4885PARP1 373/4885 |
| US-20120172575-A1 | ALKYNES AND METHODS OF REACTING ALKYNES WITH 1,3-DIPOLE-FUNCTIONAL COMPOUNDS | ALG1, ST3GAL3, B3GNT2 | HTR2A 2987/4885CYP2D6 1242/4885PARP1 373/4885 |
| US-20210401997-A1 | DOSING REGIMENS AND RELATED COMPOSITIONS AND METHODS | C1QBP, C3AR1, C9 | HTR2A 2028/4885CYP2D6 3342/4885PARP1 179/4885 |
| US-20230302038-A1 | RNAS FOR COMPLEMENT INHIBITION | SNRPE, RNASE1, SNRPF | HTR2A 4421/4885CYP2D6 4751/4885PARP1 1164/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.